NCT02143622View on ClinicalTrials.gov

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL

LJM716

antibody

BIOLOGICAL

cetuximab

antibody

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY